Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Transgene
- Target Recruit Count
- 166
- Registration Number
- NCT02355951
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Biological: TG4010Drug: placebo
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Transgene
- Target Recruit Count
- 222
- Registration Number
- NCT01383148
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Germany
🇭🇺Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
🇭🇺Petz Aladár Megyei Oktató kórház, Győr, Hungary
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Drug: pegylated interferon and ribavirinBiological: TG4040 + SOC
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Transgene
- Target Recruit Count
- 140
- Registration Number
- NCT01055821
- Locations
- 🇩🇪
Hospital, Hannover, Germany
Trial of TG4023 Combined With Flucytosine in Liver Tumors
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Transgene
- Target Recruit Count
- 16
- Registration Number
- NCT00978107
- Locations
- 🇫🇷
Hôpitaux Civils de Colmar, Colmar, France
🇫🇷Institut Paoli Calmette,, Marseille, France
🇫🇷Hôpitaux Civils de Lyon,, Pierre Benite, France
Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2010-09-03
- Lead Sponsor
- Transgene
- Target Recruit Count
- 42
- Registration Number
- NCT00529321
- Locations
- 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷Hopital A. Michallon, La Tronche, France
🇫🇷Hôpital de l'Hôtel Dieu, Nantes, France
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: MVA-MUC1-IL2Drug: 1st line Chemotherapy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Transgene
- Target Recruit Count
- 148
- Registration Number
- NCT00415818
- Locations
- 🇵🇱
Oddział Chemioterapii, Krakow, Poland
🇵🇱Dolnośląskie Centrum, Wrocław, Poland
🇫🇷Centre François Baclesse, Caen, France
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
- Conditions
- Lymphoma, B-Cell
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Transgene
- Target Recruit Count
- 13
- Registration Number
- NCT00394693
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Northwestern University Medical School, Chicago, Illinois, United States
🇫🇷Hopital Lapeyronie, Montpellier, France
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2006-11-02
- Lead Sponsor
- Transgene
- Target Recruit Count
- 50
- Registration Number
- NCT00040170
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States